Global Health Limited (MEDANTA) AI Stock Analysis

Top Page

Global Health Limited

(NSE:MEDANTA)

Select Model

Rating:70Outperform

Price Target:INR 1,396.00▲(10.00% Upside)

Action:upgraded

Date:08/17/26

The score is primarily supported by strong financial momentum (growth and profitability) and constructive technical trend signals, but it is held back by stretched valuation (high P/E and minimal dividend yield) and the recent deterioration in free cash flow (negative in 2026).

Positive Factors

Sustained Revenue GrowthConsistent revenue expansion indicates continuing demand for Medanta’s hospital, clinical, diagnostic, and related services. Healthy double-digit growth in the latest years can support operating leverage, capacity investment, and stronger competitive positioning over the next several quarters.

Negative Factors

Negative Free Cash FlowThe shift to negative free cash flow reduces near-term financial flexibility and may increase reliance on cash reserves or external funding for expansion. Although it is consistent with higher investment spending, sustained weakness would limit the company’s ability to fund growth while maintaining balance-sheet strength.

Global Health Limited (MEDANTA) vs. iShares MSCI India ETF (INDA)

Market Cap: INR 361.74B
Dividend Yield: 0.08%
Average Volume (3M): 42.12K
Price to Earnings (P/E): 61.4
Beta (1Y): 0.70
Revenue Growth: 21.27%
EPS Growth: 4.09%
Country: India
Employees: 12,600
Sector: General
Sector Strength: 55
Industry: Medical - Care Facilities

Global Health Limited Business Overview & Revenue Model

Company Description

Operating throughout India, Global Health Limited, known by its Medanta brand, stands as a prominent multi-specialty tertiary care provider. The company delivers a comprehensive suite of healthcare services, with particular expertise in cardiology, n...

How the Company Makes Money

Medanta primarily makes money by delivering healthcare services through its hospitals. The core revenue stream is patient-care income, which includes (i) inpatient hospital services such as bed/room charges, intensive care, operating theatre and proc...

Global Health Limited Financial Statement Overview

Summary

Strong multi-year revenue growth and meaningfully improved profitability support a solid fundamental profile. Balance sheet leverage improved versus earlier years, but the uptick in total debt in 2026 and margin variability add some risk. The biggest drag is cash-flow quality: free cash flow turned negative in 2026 after being positive in prior years, reducing near-term flexibility.

Income Statement

82Very Positive

Balance Sheet

74Positive

Cash Flow

63Positive

Financial statement breakdown
Breakdown	TTM	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Income Statement
Total Revenue	46.83B	44.10B	36.37B	32.41B	26.83B	21.67B
Gross Profit	28.92B	20.95B	27.57B	24.82B	20.58B	16.24B
EBITDA	10.59B	10.17B	9.05B	8.72B	6.77B	4.90B
Net Income	5.56B	5.56B	4.81B	4.78B	3.26B	1.96B
Balance Sheet
Total Assets	0	59.05B	47.66B	43.04B	41.16B	31.46B
Cash, Cash Equivalents and Short-Term Investments	11.30B	11.30B	10.51B	11.56B	12.60B	5.12B
Total Debt	0	11.90B	7.18B	8.02B	11.22B	11.09B
Total Liabilities	-39.84B	19.21B	13.79B	13.98B	16.88B	15.30B
Stockholders Equity	39.84B	39.62B	33.86B	29.06B	24.28B	16.16B
Cash Flow
Free Cash Flow	-841.82M	-2.25B	1.07B	3.33B	4.09B	367.87M
Operating Cash Flow	3.29B	7.53B	6.24B	6.12B	6.45B	3.11B
Investing Cash Flow	464.62M	-11.43B	-7.21B	-4.41B	-3.42B	-4.21B
Financing Cash Flow	1.54B	2.87B	-972.26M	-5.14B	3.46B	1.60B

Global Health Limited Technical Analysis

Technical Analysis SentimentNeutral

Last Price1269.05

Price Trends

50DMA1377.80Negative

100DMA1362.05Negative

200DMA1243.84Positive

Market Momentum

MACD-36.37Negative

RSI44.04Neutral

STOCH85.52Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:MEDANTA, the sentiment is Neutral. The current price of 1269.05 is below the 20-day moving average (MA) of 1271.74, below the 50-day MA of 1377.80, and above the 200-day MA of 1243.84, indicating a neutral trend. The MACD of -36.37 indicates Negative momentum. The RSI at 44.04 is Neutral, neither overbought nor oversold. The STOCH value of 85.52 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:MEDANTA.

Global Health Limited Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

IN:MEDANTA against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IN:ASTERDM	73Outperform	INR 595.70B	110.40	―	0.59%	15.70%	-2.76%
IN:MEDANTA	70Outperform	INR 341.22B	61.37	―	0.08%	21.27%	4.09%
IN:NH	67Neutral	INR 351.44B	42.88	―	0.26%	71.40%	1.76%
IN:APOLLOHOSP	62Neutral	INR 1.21T	58.13	―	0.24%	17.20%	32.79%
IN:MAXHEALTH	60Neutral	INR 837.05B	57.45	―	0.23%	15.17%	1.63%
IN:FORTIS	59Neutral	INR 581.17B	55.34	―	0.13%	17.50%	20.65%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%

* General Sector Average

Performance Comparison

IN:MEDANTA and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
IN:MEDANTA	Global Health Limited	1269.05	-6.25	-0.49%
IN:APOLLOHOSP	Apollo Hospitals Enterprise Limited	8400.00	594.57	7.62%
IN:ASTERDM	Aster DM Healthcare Ltd.	683.40	4.80	0.71%
IN:FORTIS	Fortis Healthcare Ltd.	769.80	-259.46	-25.21%
IN:MAXHEALTH	Max Healthcare Institute Ltd	860.00	-284.47	-24.86%
IN:NH	Narayana Hrudayalaya Ltd.	1719.70	-62.04	-3.48%

Global Health Limited Corporate Events

Global Health Secures Ghaziabad Land for Planned 350-Plus Bed Medanta Hospital

Sep 28, 2026

Global Health Limited has secured a 10,560.36 square meter freehold land parcel in Siddharth Vihar Yojna, Ghaziabad, from the Uttar Pradesh Housing and Development Board for approximately Rs 165.82 crore through an online auction. The site is planned...

Global Health Files ESG-Focused Business Responsibility and Sustainability Report for FY 2025-26

Aug 21, 2026

Global Health Limited has submitted its Business Responsibility and Sustainability Report for the 2025-26 financial year to the BSE and NSE in compliance with SEBI’s disclosure regulations. The filing signals the company’s continued align...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 17, 2026

Global Health Limited AI Stock Analysis

Top Page